Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radiotherapy

Epidemiology

Volumn 7, Issue 1, 1996, Pages 9-13

  Sosco, Annie J ^a,b   Chaplain, Gilles ^c   Amoros, Emmanuelle ^a   Saez, Simone ^d  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b Department of Oncology   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

^d INSTITUT PASTEUR   (France)

Author keywords

breast cancer; endometrial cancer; radiotherapeutic castration; tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0030024274     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001648-199601000-00003     Document Type: Article

References (24)

1. Saez S. Les antiœstrogènes. Presse Méd 1984;13:1261-1265.
2. Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984;25:127-205.
3. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15,71-85.
4. Fisher B, Lawrence DL, Redmond C. Recent developments in the use of systemic adjuvant therapy for the treatment of breast cancer. Semin Oncol 1992;19:263-277.
5. Sasco AJ. Quelques réflexions sur le ròle cancérogène potentiel du tamoxifène. Bull Cancer 1994;81:706-714.
6. Fugh-Berman A, Epstein S. Tamoxifen for breast cancer prevention: a cautionary review. Rev Endocr Rel Cancer 1993;43:43-55.
7. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991;83:1013-1017.
8. Andersson M, Storm HH, Mouridsen HT. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 1992;31:259-263.
9. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, Other NSABP Contributors. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14- J Natl Cancer Inst 1994;86:527-537.
10. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Rotstein S, Hjalmar ML, Perbeck L. Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J Clin Oncol 1991;9:1740-1748.
11. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N, for the Stockholm Breast Cancer Study Group. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995;87:645-651.
12. Rydén S, Fernö M, Möller T, Aspegren K, Bergljung L, Killander D, Landberg T. Long-term effects of adjuvant tamoxifen and/or radiotherapy: The South Sweden Breast Cancer Trial. Acta Oncol 1992;31:271-274.
13. Cummings FJ, Gray R, Tormey DC, Davis TE, Volk H, Harris J, Falkson G, Bennett JM. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J Clin Oncol 1993;11:29-35.
14. Stewart HJ for the Scottish Cancer Trials Breast Group. The Scottish Trial of adjuvant tamoxifen in node-negative breast cancer. Natl Cancer Inst Monogr 1992;11:117-120.
15. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet 1988;1:563.
16. Hardell L. Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri. Lancet 1988;1:1432.
17. Hardell L. Tamoxifen as a risk factor for endometrial cancer. Cancer 1990;66:1661.
18. van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LALM, Gimbrère CHF, Otter R, Schouten LJ, Dambuis RAM, Bontenbal M, Diepenhorst FW, van den Belt-Dusebout AW, van Tinteren H. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-452.
19. Sasco AJ, Fontanière B, Charbaut-Lagarde MO, Kliebsch U, Hamandjian P, Cornu-Liigrin AE, Schnebelen JP, Sciortino V, Fabry J, A systematic survey of. breast cancer incidence in the 'département' of Rhône, France. Eur J Cancer 1991;27:1696-1701,
20. Chaplain G, Cuisenier J, Milan C, Arveux T, Le Dorze C, Dusserre P, Michiels R, Pansiot F, Guerrin J. Evolution de l'incidence, du stade de diagnostic et des traitements du cancer du sein dans le département de la Côte d'Or de 1982 à 1990: registre des cancers gynécologiques de Côte d'Or. Rev Epidémiol Santé Publique 1993;41:S37-S38.
21. Hardell L. Endometrial cancer and tamoxifen. Lancet 1994;343:978.
22. Ewertz M, Mouridsen HT. Second cancer following cancer of the female breast in Denmark, 1943-80. Natl Cancer Inst Monogr 1985;68:325-329.
23. Chaplain G, Cuisenier J, Milan C, Small M, Jonaray P, Collin F, Déchelotte D, Michiels-Marzais D, Jahier J, Michiels R. Cancers du corps de l'utérus dans le département de la Côte d'Or 1982-1990: incidence, stade clinique et survie. Bull Cancer 1994;81:691-697.
24. Fornander T, Hellström AC, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993;85:1850-1855.